New research reveals that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end conventional lifestyle regimens.
Findings released in a leading health publication shows that while overweight people can lose substantial amounts of their body weight while using the jabs, the weight returns at an average rate of nearly a kilo each month after stopping.
"Individuals buying such treatments need to be cognizant of the potential of quick weight regain when the medication is stopped," stated expert Dr. Susan Jebb.
That rate of regain means a return to starting weight within about one and a half years.
Analyzing Treatments
The analysis, which looked at dozens of trials involving over 9,000 of participants, compared the effects of the injectable medications with other pills.
The team point out that people who lose weight through diet and exercise generally see a more gradual weight regain—approximately 0.1 kg a month—once they finish.
The Reason for the Rapid Regain
Doctors suggest the mode of action of the injections accounts for the heightened rebound.
These medications copy a body's own chemical called glucagon-like peptide-1, which helps regulate appetite.
"Long-term administration of GLP-1 levels several times higher than normal might result in the system to produce less of its endogenous GLP-1, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this GLP-1 'fix' means appetite is uncontrolled, making overeating far more likely."
A Chronic Disease?
The NHS advise the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, considering the significant potential of relapse, the treatment might need to be life-long.
This perspective is supported by pharmaceutical companies, who state that the findings "emphasize the persistent character of obesity," comparing it to managing diseases like hypertension.
User Experiences
People who have discontinued the jabs describe a sudden return of hunger.
"I experienced a switch activating and you become starving," described one woman.
The struggle is compounded if patients have not established sustainable dietary or behavioural modifications during therapy.
Significant Use
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Adoption is greater among women than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than public health services.
Finally, researchers caution that while these medications are potent tools for shedding pounds, they are not a standalone solution and long-term success likely depends on integrated lifestyle support.
